Q2 FY2022 Financial Results

from the beginning

Q2 FY2022 Financial Results

• Featuring

• Forward-looking statements

• CORE PRINCIPLE and WORLD VISION

1. Q2 Results and FY2022 Forecast

• Summary

Summary@

• Q2 FY2022 Consolidated results

Q2 FY2022 Consolidated results@

• Q2 FY2022 Sales bridge

• Q2 FY2022 Core operating profit bridge

Q2 FY2022 Core operating profit bridge@

• FY2022 Outlook: Revised

FY2022 Outlook: Revised@

FY2022 Outlook: Revised@

• Shareholder returns

2. R&D Update

• R&D update

R&D update@

• STN1011402: epinastine HCl (ophthalmic cream)

3. Regrowth Agenda

• Regrowth agenda

Regrowth agenda@

Regrowth agenda@

Regrowth agenda@

• Improving profitability (Americas business)

Improving profitability (Americas business)@

• Improve profitability (structural reforms)

Improve profitability (structural reforms)@

• Target KPI

• Outlook

Outlook@

Q&A

• Q&A 1

Q&A 1@

Q&A 1@

Q&A 1@

• Q&A 2

Q&A 2@

Q&A 2@

Q&A 2@

Q&A 2@

Q&A 2@

• Q&A 3

Q&A 3@

Q&A 3@

Q&A 3@

• Q&A 4

Q&A 4@

Q&A 4@

Q&A 4@

Q&A 4@

• Q&A 5

Q&A 5@

Q&A 5@

Q&A 5@

Q&A 5@

• Q&A 6

Q&A 6@

Q&A 6@

Q&A 6@

Q&A 6@

Appendix

• Q2 FY2022: Region review (Japan)

• Q2 FY2022: Region review (China)

• Q2 FY2022: Region review (Asia)

• Q2 FY2022: Region review (EMEA)

• Q2 FY2022: Region review (Americas)

• Q2 FY2022 financial position

• Q2 FY2022 Cash flow

• Foreign exchange rate assumptions and sensitivities

• Q2 FY2022 revenue by region (YTD)

• Prescription Ophthalmic Market in Japan (Oct. 2021 - Sep. 2022)

• Current status of global development(1)

• Current status of global development(2)

• Current status of global development(3)

• Current status of global development(4)

• STN1011402: epinastine HCl (ophthalmic cream)(1)

• STN1011402: epinastine HCl (ophthalmic cream)(2)

• STN1011402: epinastine HCl (ophthalmic cream)(3)

• STN1011402: epinastine HCl (ophthalmic cream)(4)

• STN1011402: epinastine HCl (ophthalmic cream)(5)

• STN1014100 (olodaterol hydrochloride)

@